Inion Oy

("Inion or the "Company")

Results of the Annual General Meeting

Tampere, Finland and Guildford, UK. 30 June 2009. Inion Oy announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.

The following resolutions were passed at the AGM:

I Matters belonging to the Annual General Meeting in accordance with 12 § of the

Articles of Association

1. That the annual accounts for the year ended 31 December 2008 be adopted;

2. That no dividend be declared in respect of the year 2008;

3. That Directors and the Chief Executive Officer be discharged from liability;

4. Number of Directors to be seven (7);

5 – 11. Re-election of the following as Directors: Ian Paling, David Anderson, James Beery, Julien Cotta, Peter Jensen, Chris Lee, Markku Silén as Director;

12. Resolve on the remuneration to the auditors, PricewaterhouseCoopers Oy.

II Proposal by the Board to amend the Articles of Association

13. Amendment of the Articles of Association as follows:

13a) 5 § Restrictions of the Board of Directors’ borrowing powers and 16 §

Redemption obligation: Correction of the typing errors in the current provisions.

13b) 11 §: The main content of the proposal is that the notice period for extraordinary general meetings shall be extended from seventeen (17) days to twenty one (21) days and as regards Finland, the meeting notice will be published only in one (1) daily newspaper published in Finland instead of two (2) different newspapers.

-ends-

For further information, please contact:

Inion Oy

Chris Lee, Chief Executive Officer

Julien Cotta, Chief Financial Officer

Tel: +44 (0)1483 685390

Citigate Dewe Rogerson

Mark Swallow / Helena Galilee / David Dible

Tel: +44 (0)207 638 9571

About Inion (www.inion.com)

Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments.

Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation.

The Company has offices in the UK and US, and its head office, R&D and production facilities are in Tampere, Finland.

The Company has offices in the UK and US, and its head office, R&D and production facilities are in Tampere, Finland.

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.

09_INI_14 AGM Results.pdf (20.7 kilobytes)